| Trial ID: | L1473 |
| Source ID: | NCT02539160
|
| Associated Drug: |
Ticagrelor
|
| Title: |
Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02539160/results
|
| Conditions: |
Coronary Artery Disease|Diabetes Mellitus
|
| Interventions: |
DRUG: ticagrelor
|
| Outcome Measures: |
Primary: Platelet Reactivity Measured by Vasodilator Stimulated Phosphoprotein (VASP) Platelet Reactivity Index (PRI %), The primary end point of the study was platelet reactivity assessed by VASP-PRI following treatment with ticagrelor 90mg between DM-CKD and DM-non-CKD cohorts. PRI % is a measure of platelet reactivity, where higher PRI levels represent higher platelet reactivity and lower effect of antiplatelet medications. PRI greater than 50% represents inadequate response to antiplatelet medications., 7 days | Secondary: Platelet Reactivity Measured by VerifyNow P2Y12, Platelet reactivity assessed by VerifyNow P2Y12 following treatment with ticagrelor 90mg or 60 mg between DM-CKD and DM-non-CKD cohorts. Results are expressed in P2Y12 reaction units (PRU). PRU is a measure of platelet reactivity, where higher PRU levels represent higher platelet reactivity and lower effect of antiplatelet medications. PRU greater than 208 represents inadequate response to antiplatelet medications., 7 days
|
| Sponsor/Collaborators: |
Sponsor: University of Florida
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
101
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-02
|
| Completion Date: |
2020-06-17
|
| Results First Posted: |
2022-01-28
|
| Last Update Posted: |
2022-01-28
|
| Locations: |
University of Florida, Jacksonville, Florida, 32209, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02539160
|
